Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: Identification of novel nuclear cofactors of antiestrogen-erα complexes by interaction proteomics

Journal of Proteome Research

Volumn 12, Issue 1, 2013, Pages 421-431

  Cirillo, Francesca ^a,b   Nassa, Giovanni ^a,b   Tarallo, Roberta ^a   Stellato, Claudia ^a,e   De Filippo, Maria Rosaria ^b   Ambrosino, Concetta ^c   Baumann, Marc ^d,f   Nyman, Tuula A ^f   Weisz, Alessandro ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b IRCCS SDN   (Italy)

^c UNIVERSITY OF SANNIO   (Italy)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antiestrogen; Breast cancer; Deleted in breast cancer gene 1 KIAA1967; Estradiol; Estrogen receptor; Histone H3 methyltransferase DOT1L; ICI 182,780; Pyruvate dehydrogenase E1 component PDHA1; Raloxifene; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; CANCER CELL; CRYSTALLOGRAPHY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL NUCLEUS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; PROTEIN CONFORMATION; PROTEOMICS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84874084179     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300753u     Document Type: Article

References (68)

1. McKenna, N. J.; O'Malley, B. W. Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann. N. Y. Acad. Sci. 2001, 949, 3-5.
2. Cicatiello, L.; Addeo, R.; Sasso, A.; Altucci, L.; Petrizzi, V. B.; Borgo, R.; Cancemi, M.; Caporali, S.; Caristi, S.; Scafoglio, C.; Teti, D.; Bresciani, F.; Perillo, B.; Weisz, A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol. Cell. Biol. 2004, 24, 7260-7274.
3. Cicatiello, L.; Mutarelli, M.; Grober, O. M.; Paris, O.; Ferraro, L.; Ravo, M.; Tarallo, R.; Luo, S.; Schroth, G. P.; Seifert, M.; Zinser, C.; Chiusano, M. L.; Traini, A.; De Bortoli, M.; Weisz, A. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am. J. Pathol. 2010, 176, 2113-2130.
4. Greene, G. L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231, 1150-1154.
5. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392, 49-53.
6. Speirs, V.; Adams, I. P.; Walton, D. S.; Atkin, S. L. Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J. Clin. Endocrinol. Metab. 2000, 85, 1601-1605.
7. Barkhem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson, J.; Nilsson, S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
8. McInerney, E. M.; Weis, K. E.; Sun, J.; Mosselman, S.; Katzenellenbogen, B. S. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998, 139, 4513-4522.
9. McCarty, K. S., Jr.; Kinsel, L. B.; Georgiade, G.; Leight, G.; McCarty, K. S., Sr. Long-term prognostic implications of sex-steroid receptors in human cancer. Prog. Clin. Biol. Res. 1990, 322, 279-293.
10. Bentrem, D.; Dardes, R.; Liu, H.; MacGregor-Schafer, J.; Zapf, J.; Jordan, V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 2001, 142, 838-846.
11. Waters, E. A.; McNeel, T. S.; Stevens, W. M.; Freedman, A. N. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res. Treat. 2012, 134 (2), 875-80.
12. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
13. Kumar, V.; Green, S.; Stack, G.; Berry, M.; Jin, J. R.; Chambon, P. Functional domains of the human estrogen receptor. Cell 1987, 51, 941-951.
14. Berry, M.; Metzger, D.; Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promotercontext dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9, 2811-2818.
15. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
16. Greschik, H.; Flaig, R.; Renaud, J. P.; Moras, D. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J. Biol. Chem. 2004, 279, 33639-33646.
17. Kumar, R.; Johnson, B. H.; Thompson, E. B. Overview of the structural basis for transcription regulation by nuclear hormone receptors. Essays Biochem. 2004, 40, 27-39.
18. Wrenn, C. K.; Katzenellenbogen, B. S. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem. 1993, 268, 24089-24098.
19. Feng, W.; Ribeiro, R. C.; Wagner, R. L.; Nguyen, H.; Apriletti, J. W.; Fletterick, R. J.; Baxter, J. D.; Kushner, P. J.; West, B. L. Hormonedependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280, 1747-1749.
20. Clemons, M.; Danson, S.; Howell, A. Tamoxifen (?Nolvadex?): a review. Cancer Treat Rev. 2002, 28, 165-180.
21. Ward, H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1973, 1, 13-14.
22. Strasser-Weippl, K.; Goss, P. E. Advances in adjuvant hormonal therapy for postmenopausal women. J. Clin. Oncol. 2005, 23, 1751-1759.
23. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev.. 2008; CD000486.
24. Fisher, B.; Dignam, J.; Bryant, J.; Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst. 2001, 93, 684-690.
25. Smith, M. R. Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev. Urol. 2005, 7 (Suppl 3), S30-5.
26. Sengupta, S.; Jordan, V. C. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv. Exp. Med. Biol. 2008, 630, 206-219.
27. Johnston, S. R. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 1997, 8, 911-930.
28. Moen, M. D.; Keating, G. M. Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs 2008, 68, 2059-2083.
29. Johnston, S. R. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin. Cancer Res. 2001, 7 (12 Suppl), 4376s-4387s discussion 4411s-4412s..
30. Howell, A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr.-Relat. Cancer 2006, 13, 689-706.
31. Carlson, R. W. The history and mechanism of action of fulvestrant. Clin. Breast Cancer 2005, 6 (Suppl1), S5-8.
32. Gradishar, W. J.; Sahmoudv, T. Current and future perspectives on fulvestrant. Clin. Breast Cancer 2005, 6 (Suppl 1), S23-9.
33. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; Li, Y. L.; Gustafsson, J. A.; Carlquist, M. Structural insights into the mode of action of a pure antiestrogen. Structure 2001, 9, 145-153.
34. Schultz-Norton, J. R.; Ziegler, Y. S.; Likhite, V. S.; Yates, J. R.; Nardulli, A. M. Isolation of novel coregulatory protein networks associated with DNA-bound estrogen receptor alpha. BMC Mol. Biol. 2008, 9, 97.
35. Cheng, P. C.; Chang, H. K.; Chen, S. H. Quantitative nanoproteomics for protein complexes (QNanoPX) related to estrogen transcriptional action. Mol. Cell. Proteomics. 2010, 9, 209-224.
36. Ambrosino, C.; Tarallo, R.; Bamundo, A.; Cuomo, D.; Franci, G.; Nassa, G.; Paris, O.; Ravo, M.; Giovane, A.; Zambrano, N.; Lepikhova, T.; Ja?nne, O. A.; Baumann, M.; Nyman, T. A.; Cicatiello, L.; Weisz, A. Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol. Cell. Proteomics 2010, 9, 1352-1367.
37. Tarallo, R.; Bamundo, A.; Nassa, G.; Nola, E.; Paris, O.; Ambrosino, C.; Facchiano, A.; Baumann, M.; Nyman, T. A.; Weisz, A. Identification of proteins associated with ligand-activated estrogen receptor ? in human breast cancer cell nuclei by tandem affinity purification and nano LC-MS/MS. Proteomics 2011, 11, 172-179.
38. Addeo, R.; Altucci, L.; Battista, T.; Bonapace, I. M.; Cancemi, M.; Cicatiello, L.; Germano, D.; Pacilio, C.; Salzano, S.; Bresciani, F.; Weisz, A. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun. 1996, 220, 864-870.
39. Nassa, G.; Tarallo, R.; Ambrosino, C.; Bamundo, A.; Ferraro, L.; Paris, O.; Ravo, M.; Guzzi, P. H.; Cannataro, M.; Baumann, M.; Nyman, T. A.; Nola, E.; Weisz, A. A large set of estrogen receptor ?-interacting proteins identified by tandem affinity purification in hormone-responsive human breast cancer cell nuclei. Proteomics 2011, 11, 159-165.
40. Shevchenko, A.; Wilm, M.; Vorm, O.; Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
41. Nyman, T. A.; Rosengren, A.; Syyrakki, S.; Pellinen, T. P.; Rautajoki, K.; Lahesmaa, R. A proteome database of human primary T helper cells. Electrophoresis 2001, 22, 4375-4382.
42. Sun, H.; Fang, H.; Chen, T.; Perkings, R.; Tong, W. GOFFA: Gene Ontology For Functional Analysis-Software for gene ontologybased functional analysis of genomic and proteomic data. BMC Bioinformatics 2006, 7, S23.
43. Grober, O. M.; Mutarelli, M.; Giurato, G.; Ravo, M.; Cicatiello, L.; De Filippo, M. R.; Ferraro, L.; Nassa, G.; Papa, M. F.; Paris, O.; Tarallo, R.; Luo, S.; Schroth, G. P.; Benes, V.; Weisz, A. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 2011, 12, 36.
44. Paris, O.; Ferraro, L.; Grober, O. M.; Ravo, M.; De Filippo, M. R.; Giurato, G.; Nassa, G.; Tarallo, R.; Cantarella, C.; Rizzo, F.; Di Benedetto, A.; Mottolese, M.; Benes, V.; Ambrosino, C.; Nola, E.; Weisz, A. Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. Oncogene. 2012, [Epub ahead of print].
45. Rigaut, G.; Shevchenko, A.; Rutz, B.; Wilm, M.; Mann, M.; Se?raphin, B. A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 1999, 17, 1030-1032.
46. Gavin, A. C.; Bo?sche, M.; Krause, R.; Grandi, P.; Marzioch, M.; Bauer, A.; Schultz, J.; Rick, J. M.; Michon, A. M.; Cruciat, C. M.; Remor, M.; Ho?fert, C.; Schelder, M.; Brajenovic, M.; Ruffner, H.; Merino, A.; Klein, K.; Hudak, M.; Dickson, D.; Rudi, T.; Gnau, V.; Bauch, A.; Bastuck, S.; Huhse, B.; Leutwein, C.; Heurtier, M. A.; Copley, R. R.; Edelmann, A.; Querfurth, E.; Rybin, V.; Drewes, G.; Raida, M.; Bouwmeester, T.; Bork, P.; Seraphin, B.; Kuster, B.; Neubauer, G.; Superti-Furga, G. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415, 141-147.
47. Nassa, G.; Tarallo, R.; Guzzi, P. H.; Ferraro, L.; Cirillo, F.; Ravo, M.; Nola, E.; Baumann, M.; Nyman, T. A.; Cannataro, M.; Ambrosino, C.; Weisz, A. Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in breast cancer cells. Mol. Biosyst. 2011, 7, 667-676.
48. Dauvois, S.; Danielian, P. S.; White, R.; Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 4037-4041.
49. Dauvois, S.; White, R.; Parker, M. G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106, 1377-1388.
50. Kocanova, S.; Mazaheri, M.; Caze-Subra, S.; Bystricky, K. Ligands specify estrogen receptor alpha nuclear localization and degradation. BMC Cell Biol. 2010, 11, 98.
51. Cicatiello, L.; Scafoglio, C.; Altucci, L.; Cancemi, M.; Natoli, G.; Facchiano, A.; Iazzetti, G.; Calogero, R.; Biglia, N.; De Bortoli, M.; Sfiligoi, C.; Sismondi, P.; Bresciani, F.; Weisz, A. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J. Mol. Endocrinol. 2004, 32, 719-775.
52. Scafoglio, C.; Ambrosino, C.; Cicatiello, L.; Altucci, L.; Ardovino, M.; Bontempo, P.; Medici, N.; Molinari, A. M.; Nebbioso, A.; Facchiano, A.; Calogero, R. A.; Elkon, R.; Menini, N.; Ponzone, R.; Biglia, N.; Sismondi, P.; De Bortoli, M.; Weisz, A. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J. Cell Biochem. 2006, 98, 1163-1184.
53. Me?tivier, R.; Penot, G.; Hu?bner, M. R.; Reid, G.; Brand, H.; Kos, M.; Gannon, F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115, 751-763.
54. Kim, J. E.; Chen, J.; Lou, Z. DBC1 is a negative regulator of SIRT1. Nature 2008, 451, 583-586.
55. Ford, J.; Jiang, M.; Milner, J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005, 65, 10457-10463.
56. Ota, H.; Tokunaga, E.; Chang, K.; Hikasa, M.; Iijima, K.; Eto, M.; Kozaki, K.; Akishita, M.; Ouchi, Y.; Kaneki, M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25, 176-185.
57. Pruitt, K.; Zinn, R. L.; Ohm, J. E.; McGarvey, K. M.; Kang, S. H.; Watkins, D. N.; Herman, J. G.; Baylin, S. B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006, 2, e40.
58. Lim, C. S. SIRT1: tumor promoter or tumor suppressor? Med. Hypotheses 2006, 67, 341-344.
59. Yeung, F.; Hoberg, J. E.; Ramsey, C. S.; Keller, M. D.; Jones, D. R.; Frye, R. A.; Mayo, M. W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23, 2369-2380.
60. Kuzmichev, A.; Margueron, R.; Vaquero, A.; Preissner, T. S.; Scher, M.; Kirmizis, A.; Ouyang, X.; Brockdorff, N.; Abate-Shen, C.; Farnham, P.; Reinberg, D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 1859-1864.
61. Chen, W. Y.; Wang, D. H.; Yen, R. C.; Luo, J.; Gu, W.; Baylin, S. B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123, 437-448.
62. Chueh, F. Y.; Leong, K. F.; Cronk, R. J.; Venkitachalam, S.; Pabich, S.; Yu, C. L. Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription. Cell. Signalling 2011, 23, 1170-1178.
63. Hu, Q.; Kwon, Y. S.; Nunez, E.; Cardamone, M. D.; Hutt, K. R.; Ohgi, K. A.; Garcia-Bassets, I.; Rose, D. W.; Glass, C. K.; Rosenfeld, M. G.; Fu, X. D. Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 19199-19204.
64. Planas-Silva, M. D.; Waltz, P. K. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 104, 11-21.
65. Steger, D. J.; Lefterova, M. I.; Ying, L.; Stonestrom, A. J.; Schupp, M.; Zhuo, D.; Vakoc, A. L.; Kim, J. E.; Chen, J.; Lazar, M. A.; Blobel, G. A.; Vakoc, C. R. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 2008, 28, 2825-2839.
66. Bernt, K. M.; Armstrong, S. A. A role for DOT1L in MLLrearranged leukemias. Epigenomics 2011, 3, 667-670.
67. Chang, M. J.; Wu, H.; Achille, N. J.; Reisenauer, M. R.; Chou, C. W.; Zeleznik-Le, N. J.; Hemenway, C. S.; Zhang, W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010, 70, 10234-10242.
68. Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.; Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.; Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K. M.; Tseng, J. C.; Kung, A. L.; Armstrong, S. A.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011, 20, 53-56.